PedAM
Pediatric Disease Annotations & Medicines
| polymyositis | ||||
| Disease ID | 115 |
|---|---|
| Disease | polymyositis |
| Definition | Diseases characterized by inflammation involving multiple muscles. This may occur as an acute or chronic condition associated with medication toxicity (DRUG TOXICITY); CONNECTIVE TISSUE DISEASES; infections; malignant NEOPLASMS; and other disorders. The term polymyositis is frequently used to refer to a specific clinical entity characterized by subacute or slowly progressing symmetrical weakness primarily affecting the proximal limb and trunk muscles. The illness may occur at any age, but is most frequent in the fourth to sixth decade of life. Weakness of pharyngeal and laryngeal muscles, interstitial lung disease, and inflammation of the myocardium may also occur. Muscle biopsy reveals widespread destruction of segments of muscle fibers and an inflammatory cellular response. (Adams et al., Principles of Neurology, 6th ed, pp1404-9) |
| Synonym | multiple myositis myositides, multiple myositis, multiple neuromyositis neuromyositis-retired neuromyositis-retired (disorder) pm - polymyositis polymyositides polymyositis (disorder) polymyositis [disease/finding] |
| Orphanet | |
| DOID | |
| UMLS | C0085655 |
| MeSH | |
| SNOMED-CT | |
| Comorbidity | UMLS | Disease | Sentences' Count(Total Sentences:58) C0024115 | lung disease | 12 C0206062 | interstitial lung disease | 12 C0026848 | myopathy | 5 C0019158 | hepatitis | 4 C0003873 | rheumatoid arthritis | 3 C0009782 | connective tissue disorder | 3 C0003864 | arthritis | 2 C0241910 | autoimmune hepatitis | 2 C0009782 | connective tissue disorders | 2 C0011633 | dermatomyositis | 2 C0027121 | myositis | 2 C0019163 | hepatitis b | 2 C0007102 | colon cancer | 2 C0026896 | myasthenia gravis | 2 C0020538 | hypertension | 2 C0027059 | myocarditis | 2 C0032285 | pneumonia | 2 C0206062 | interstitial lung diseases | 1 C0752166 | bardet-biedl syndrome | 1 C0008312 | primary biliary cirrhosis | 1 C0020676 | hypothyroidism | 1 C0027121 | inflammatory myopathy | 1 C0677607 | hashimoto's thyroiditis | 1 C1527336 | sjogren's syndrome | 1 C1145670 | respiratory failure | 1 C0020542 | pulmonary hypertension | 1 C0021053 | immune disease | 1 C0009782 | connective tissue diseases | 1 C0006142 | breast cancer | 1 C0442874 | neuropathy | 1 C0456845 | non-secretory myeloma | 1 C0334254 | lymphoepithelioma | 1 C0027121 | inflammatory myopathies | 1 C0010346 | crohn's disease | 1 C0020550 | hyperthyroidism | 1 C0026848 | myopathies | 1 C0032461 | polycythaemia | 1 C0027726 | nephrotic syndrome | 1 C0026850 | muscular dystrophies | 1 C0032463 | polycythaemia vera | 1 C0027121 | muscle inflammation | 1 C0242379 | lung cancer | 1 C0024115 | pulmonary disease | 1 C0018213 | graves' disease | 1 C0026850 | muscular dystrophy | 1 C0019204 | hepatocellular carcinoma | 1 C0024115 | lung diseases | 1 C0024299 | lymphoma | 1 C0009782 | connective tissue disease | 1 C0026764 | myeloma | 1 C0011570 | depression | 1 C0085278 | antiphospholipid antibody syndrome | 1 C0034065 | pulmonary embolism | 1 C0020626 | hypoparathyroidism | 1 C0039590 | testicular cancer | 1 C0026846 | muscle atrophy | 1 C0235974 | pancreatic cancer | 1 C0376545 | hematological malignancy | 1 |
| Curated Gene | Entrez_id | Symbol | Resource(Total Genes:5) |
| Inferring Gene | (Waiting for update.) |
| Text Mined Gene | (Waiting for update.) |
| Locus | (Waiting for update.) |
| Disease ID | 115 |
|---|---|
| Disease | polymyositis |
| Manually Symptom | UMLS | Name(Total Manually Symptoms:90) C2697391 | rheumatoid arthritis C2609059 | antisynthetase syndrome C2364133 | infection C2364118 | weakness C1963229 | retinal detachment C1963220 | pulmonary hypertension C1962972 | proteinuria C1962971 | myocarditis C1962966 | retinopathy C1512411 | hepatocellular carcinoma C1420725 | thymoma C1384514 | primary aldosteronism C1290344 | nonspecific interstitial pneumonia C1145670 | respiratory failure C1112565 | pneumatosis intestinalis C0878544 | myocardial disease C0865681 | chronic myocarditis C0852949 | arteriopathy C0748159 | pulmonary involvement C0549225 | myasthenic syndrome C0520463 | chronic active hepatitis C0520459 | necrotizing enterocolitis C0442874 | neuropathy C0432474 | klinefelter's syndrome C0403457 | myoglobinuric acute renal failure C0403416 | crescentic glomerulonephritis C0398367 | kikuchi-fujimoto disease C0268123 | myoadenylate deaminase deficiency C0264886 | conduction disorders C0264886 | conduction defects C0264886 | cardiac conduction defects C0264490 | acute respiratory failure C0242770 | bronchiolitis obliterans organizing pneumonia C0238183 | atrophic thyroiditis C0235896 | pulmonary infiltrates C0231443 | musculoskeletal symptoms C0206180 | ki-1 lymphoma C0206062 | interstitial lung diseases C0206062 | interstitial lung disease C0206061 | interstitial pneumonitis C0206061 | interstitial pneumonia C0205969 | malignant thymoma C0155686 | acute myocarditis C0085786 | fibrosing alveolitis C0042769 | viral infection C0042721 | virus hepatitis C0042338 | herpes zoster C0038463 | strongyloidiasis C0037116 | silicosis C0035222 | adult respiratory distress syndrome C0034902 | pure red cell aplasia C0034155 | thrombotic thrombocytopenic purpura C0034069 | pulmonary fibrosis C0032285 | pneumonitis C0032285 | pneumonia C0032266 | pneumatosis cystoides intestinalis C0030472 | paraneoplastic syndrome C0030326 | panniculitis C0029118 | opportunistic infections C0027831 | von recklinghausen's disease C0027122 | muscle calcification C0027121 | muscle inflammation C0026916 | mycobacterium avium-intracellulare infection C0025063 | mediastinal tumor C0024305 | non-hodgkin's lymphoma C0024299 | malignant lymphoma C0024282 | lymphocytosis C0024115 | lung disease C0023283 | cutaneous leishmaniasis C0023241 | legionnaires' disease C0022660 | acute renal failure C0022408 | arthropathy C0019829 | hodgkin's disease C0018802 | congestive heart failure C0018794 | heart block C0018213 | graves' disease C0017668 | focal glomerulosclerosis C0017658 | glomerulonephritis C0017152 | gastritis C0014858 | esophageal motility disorder C0014858 | esophageal dysmotility C0011168 | dysphagia C0010403 | cryoglobulinemia C0010266 | cranial neuropathy C0008521 | choroidopathy C0008312 | primary biliary cirrhosis C0007193 | dilated cardiomyopathy C0007134 | renal cell carcinoma C0004245 | av block C0003490 | aortic arch syndrome |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:16) C0206062 | interstitial lung disease | 11 C0024115 | lung disease | 11 C0004093 | weakness | 3 C0003873 | rheumatoid arthritis | 3 C0027059 | myocarditis | 2 C0032285 | pneumonia | 2 C0009450 | infection | 2 C0008312 | primary biliary cirrhosis | 1 C0020542 | pulmonary hypertension | 1 C0018213 | graves' disease | 1 C1145670 | respiratory failure | 1 C2609059 | antisynthetase syndrome | 1 C0027121 | muscle inflammation | 1 C0206061 | interstitial pneumonia | 1 C0442874 | neuropathy | 1 C0019204 | hepatocellular carcinoma | 1 |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:15) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs10069690 | 26320593 | 7015 | TERT | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | TERT | 5 | 1279675 | C | T |
| rs10069690 | 26320593 | 2065 | ERBB3 | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | TERT | 5 | 1279675 | C | T |
| rs11171739 | 26320593 | 7015 | TERT | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 12 | 56076841 | C | T |
| rs11171739 | 26320593 | 2065 | ERBB3 | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 12 | 56076841 | C | T |
| rs13277113 | 24632671 | 640 | BLK | umls:C0085655 | BeFree | The C8orf13-BLK rs13277113A allele was associated with overall polymyositis/dermatomyositis (P<0.001, odds ratio [OR] 1.44, 95% confidence interval [CI] 1.19-1.73), as well as polymyositis (P = 0.011, OR 1.32, 95% CI 1.06-1.64) and dermatomyositis (P<0.001, OR 1.64, 95% CI 1.26-2.12). | 0.000542884 | 2014 | NA | 8 | 11491677 | G | A |
| rs13277113 | 24632671 | 83648 | FAM167A | umls:C0085655 | BeFree | The C8orf13-BLK rs13277113A allele was associated with overall polymyositis/dermatomyositis (P<0.001, odds ratio [OR] 1.44, 95% confidence interval [CI] 1.19-1.73), as well as polymyositis (P = 0.011, OR 1.32, 95% CI 1.06-1.64) and dermatomyositis (P<0.001, OR 1.64, 95% CI 1.26-2.12). | 0.000542884 | 2014 | NA | 8 | 11491677 | G | A |
| rs2292239 | 26320593 | 7015 | TERT | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | ERBB3 | 12 | 56088396 | T | G |
| rs2292239 | 26320593 | 2065 | ERBB3 | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | ERBB3 | 12 | 56088396 | T | G |
| rs2492358 | 26320593 | 2065 | ERBB3 | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 9 | 34737831 | C | T |
| rs2492358 | 26320593 | 7015 | TERT | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 9 | 34737831 | C | T |
| rs2853676 | 26320593 | 2065 | ERBB3 | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | TERT | 5 | 1288432 | T | C |
| rs2853676 | 26320593 | 7015 | TERT | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | TERT | 5 | 1288432 | T | C |
| rs951005 | 26320593 | 2065 | ERBB3 | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 9 | 34743684 | G | A |
| rs951005 | 26320593 | 6366 | CCL21 | umls:C0085655 | BeFree | A single-nucleotide polymorphism of CCL21 rs951005 T>C is associated with susceptibility of polymyositis and such patients with interstitial lung disease in a Chinese Han population. | 0.003267234 | 2015 | NA | 9 | 34743684 | G | A |
| rs951005 | 26320593 | 7015 | TERT | umls:C0085655 | BeFree | Chinese polymyositis (PM) patients (n =291), dermatomyositis (DM) patients (n=526) and ethnically-matched healthy controls (n =968) were genotyped for the CCL21 region SNPs (rs951005 and rs2492358), ERBB3 (rs2292239 and rs11171739), and TERT (rs2853676 and rs10069690), by using the Sequenom MassArray system. | 0.000271442 | 2015 | NA | 9 | 34743684 | G | A |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:1) | ||||
|---|---|---|---|---|
| HP ID | HP Name | MP ID | MP Name | Annotation |
| HP:0002206 | Pulmonary fibrosis | MP:0003141 | cardiac fibrosis;HP:0001402 | Hepatocellular carcinoma |
Mapped by homologous gene(Total Items:1) | ||||
|---|---|---|---|---|
| HP ID | HP Name | MP ID | MP Name | Annotation |
| HP:0002206 | Pulmonary fibrosis | MP:0002420 | abnormal adaptive immunity;HP:0001402 | Hepatocellular carcinoma |
Chemical(Total Drugs:11) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0085655 | ampicillin | D000667 | 69-53-4 | polymyositis | MESH:D017285 | marker/mechanism | 712173 | ||
| C0085655 | celecoxib | D000068579 | - | polymyositis | MESH:D017285 | marker/mechanism | 18583892 | ||
| C0085655 | cimetidine | D002927 | 51481-61-9 | polymyositis | MESH:D017285 | marker/mechanism | 6217424 | ||
| C0085655 | ethambutol | D004977 | 74-55-5 | polymyositis | MESH:D017285 | marker/mechanism | 18583892 | ||
| C0085655 | methotrexate | D008727 | 1959/5/2 | polymyositis | MESH:D017285 | therapeutic | 17400583 | ||
| C0085655 | octreotide | D015282 | 83150-76-9 | polymyositis | MESH:D017285 | marker/mechanism | 10509161 | ||
| C0085655 | phenytoin | D010672 | 57-41-0 | polymyositis | MESH:D017285 | marker/mechanism | 574201 | ||
| C0085655 | pravastatin | D017035 | 81093-37-0 | polymyositis | MESH:D017285 | marker/mechanism | 15199734 | ||
| C0085655 | tiopronin | D008625 | 1953/2/2 | polymyositis | MESH:D017285 | marker/mechanism | 10360187 | ||
| C0085655 | cholecalciferol | D002762 | 67-97-0 | polymyositis | MESH:D017285 | marker/mechanism | 20427501 | ||
| C0085655 | zidovudine | D015215 | 30516-87-1 | polymyositis | MESH:D017285 | marker/mechanism | 3422706 | ||
FDA approved drug and dosage information(Total Drugs:8) | ||||||||
|---|---|---|---|---|---|---|---|---|
| DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
| MESH:D017285 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
| MESH:D017285 | celebrex | celecoxib | 100MG | CAPSULE;ORAL | Prescription | None | No | No |
| MESH:D017285 | retrovir | zidovudine | 100MG | CAPSULE;ORAL | Prescription | AB | Yes | Yes |
| MESH:D017285 | retrovir | zidovudine | 50MG/5ML | SYRUP;ORAL | Prescription | AA | Yes | Yes |
| MESH:D017285 | retrovir | zidovudine | 10MG/ML | INJECTABLE;INJECTION | Prescription | AP | Yes | Yes |
| MESH:D017285 | retrovir | zidovudine | 200MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D017285 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
| MESH:D017285 | zidovudine | zidovudine | 60MG | TABLET;ORAL | Discontinued | None | No | No |
FDA labeling changes(Total Drugs:8) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
| MESH:D017285 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |
| MESH:D017285 | 12/15/2006 | celebrex | celecoxib | Relief of the signs and symptoms of juvenile rheumatoid arthritis (JRA) | New indication in 2 years and older Has not been studied in patients < 2 years, in patients with body weight < 10 kg, or in patients with active systemic features Celecoxib should be used only with caution in patients with systemic onset JRA due to the risk for serious adverse reactions including the risk of disseminated intravascular coagulation The long-term cardiovascular toxicity in children has not been evaluated; it is unknown if the long-term risk may be similar to that seen in adults New 50 mg capsule developed Information on adding contents of a capsule to applesauce. for patients with difficulty swallowing capsules Information on dose, clinical studies, PK parameters, AEs | Labeling | B | - | - | - | Pfizer | 08/23/2006 | FALSE' |
| MESH:D017285 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D017285 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D017285 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D017285 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D017285 | 09/19/2008 | retrovir syrup, capsules and tablets | zidovudine | Used in combination with 18 other antiretroviral agents for the treatment of HIV-1 infection | Dosing and administration information provided to children 6 weeks to less than 18 years of age Macrocytosis was reported in the majority of pediatric patients receiving Retrovir 180 mg/m2 every 6 hours in open-label studies New dosing regimen | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |
| MESH:D017285 | 6/11/2009 | retrovir | zidovudine | Treatment of HIV-1 infection in combination with other antiretroviral agents | Provided dosing recommendations for patients 4 weeks to < 6 weeks of age and weighing 4 kg to < 9 kg | Labeling | - | P | - | - | GlaxoSmithKline | - | TRUE' |